Battaglia Manuela, Gregori Silvia, Bacchetta Rosa, Roncarolo Maria-Grazia
San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Via Olgettina 58, Milano 20132, Italy.
Semin Immunol. 2006 Apr;18(2):120-7. doi: 10.1016/j.smim.2006.01.007. Epub 2006 Feb 7.
Peripheral tolerance is mediated by multiple mechanisms such as anergy and/or active suppression of effector T cells by T regulatory (Tr) cells. Among the CD4(+) Tr cells, T regulatory type 1 cells (Tr1) have been shown to down-modulate immune responses through production of the immunosuppressive cytokines IL-10 and TGF-beta. Tr1 cells maintain peripheral tolerance, control autoimmunity, and prevent allograft rejection and graft versus host disease (GvHD). Cellular therapy with ex vivo generated Tr1 cells has been proven to be effective in several preclinical models of T cell-mediated pathologies and therefore, represents a promising approach for clinical application. This review will summarize the new findings on Tr1 cells, the recent development of methods for their ex vivo expansion, and their potential clinical relevance as cellular therapy.
外周耐受由多种机制介导，如效应T细胞的失能和/或调节性T（Tr）细胞对其的主动抑制。在CD4(+) Tr细胞中，1型调节性T细胞（Tr1）已被证明可通过产生免疫抑制细胞因子IL-10和TGF-β来下调免疫反应。Tr1细胞维持外周耐受，控制自身免疫，并预防同种异体移植排斥和移植物抗宿主病（GvHD）。在几种T细胞介导的病理状态的临床前模型中，用体外产生的Tr1细胞进行细胞治疗已被证明是有效的，因此，这是一种有前景的临床应用方法。本综述将总结关于Tr1细胞的新发现、其体外扩增方法的最新进展以及它们作为细胞治疗的潜在临床相关性。
